Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Last trade$7.31
Day change-$0.135 (-1.81%)
Day range$7.12 – $7.70
Volume274,697
Market cap$637M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SOPH.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SOPH.
Recent news
Company coverage with links to the original publishers.
SOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
U.S. stock futures showed mixed performance on Wednesday with the Dow Jones declining while the S&P 500 and Nasdaq 100 advanced. Investors awaited the FOMC interest rate decision expected at 2:00 p.m. ET, with markets pricing a 99.6% likelihood of unchanged rates. Notable movers included La-Z-Boy surging 19.62% on strong earnings and a $300 million buyback, Amkor jumping 5.49% after signing a 10-year deal with TSMC, and SpaceX rising 3.22% following its Cursor AI acquisition.
The artificial intelligence in diagnostics market is projected to grow at a CAGR of 22.2% from 2024 to 2032, driven by the rising prevalence of chronic diseases and the increasing demand for AI tools in disease diagnosis.